INVESTOR RELATIONS

Newsroom

Featured

November 01, 2023
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

CAMBRIDGE, Mass., November 1st, 2023 — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of […]

Read More

For media inquires, please direct your media inquiries to:

EternaPR@westwicke.com

If you’re a media professional, please take advantage of our digital Media Kit. You can Download it here.

Press Releases

November 01, 2023
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
September 06, 2023
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
September 05, 2023
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
July 18, 2023
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
July 11, 2023
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
May 24, 2023
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
May 17, 2023
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 04, 2023
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 02, 2023
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
April 11, 2023
Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million
View All

Media Coverage

Episode 24 – Genetic engineering for allogeneic immunotherapy
October 24, 2023
Episode 24 – Genetic engineering for allogeneic immunotherapy
Drug Target Review
The impact of cell therapies on cancer treatments
October 13, 2023
The impact of cell therapies on cancer treatments
PMLiVE
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
September 06, 2023
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
Exec Edge
mRNA-engineered iPSC-derived Cell Therapies Hold Potential for Tackling Solid Tumors
August 14, 2023
mRNA-engineered iPSC-derived Cell Therapies Hold Potential for Tackling Solid Tumors
CGTLive
The promise of iPSC-based multi-cell therapeutics
July 05, 2023
The promise of iPSC-based multi-cell therapeutics
Drug Target Review
Tapping the Potential of mRNA in Cellular Reprogramming and Beyond
June 01, 2023
Tapping the Potential of mRNA in Cellular Reprogramming and Beyond
Longevity Technology
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel
May 24, 2023
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel
Exec Edge
Kyle Garland, PhD on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid Tumors
May 18, 2023
Kyle Garland, PhD on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid Tumors
CGTLive
Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis
May 03, 2023
Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis
Labiotech
Exclusive: RNA Firm Eterna Therapeutics Buys Neighboring Startup for $50M
May 02, 2023
Exclusive: RNA Firm Eterna Therapeutics Buys Neighboring Startup for $50M
Boston Business Journal
View All